Cargando…

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management

Checkpoint inhibitors can cause an imbalance in immune tolerance that may clinically manifest as immune-related adverse events (irAEs). These events may involve many organs and tissues, including the skin, gastrointestinal (GI) tract, liver, endocrine system, kidneys, central nervous system (CNS), e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simeone, Ester, Grimaldi, Antonio M, Festino, Lucia, Trojaniello, Claudia, Vitale, Maria G, Vanella, Vito, Palla, Marco, Ascierto, Paolo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920742/ https://www.ncbi.nlm.nih.gov/pubmed/31871619 http://dx.doi.org/10.2217/mmt-2019-0005

Ejemplares similares

Ipilimumab and Stereotactic Radiosurgery with CyberKnife(®) System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience
por: Borzillo, Valentina, et al.
Publicado: (2021)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
por: Madonna, Gabriele, et al.
Publicado: (2021)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis
por: Di Monta, Gianluca, et al.
Publicado: (2017)

Immunotherapy Assessment: A New Paradigm for Radiologists
por: Granata, Vincenza, et al.
Publicado: (2023)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
por: Trojaniello, Claudia, et al.
Publicado: (2021)

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
por: Mallardo, Domenico, et al.
Publicado: (2022)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Serious haematological toxicity during and after ipilimumab treatment: a case series
por: Simeone, Ester, et al.
Publicado: (2014)

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
por: Trojaniello, Claudia, et al.
Publicado: (2023)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas
por: Ottaviano, Margaret, et al.
Publicado: (2022)

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
por: Carlino, Matteo S, et al.
Publicado: (2016)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
por: Mallardo, Domenico, et al.
Publicado: (2023)

PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
por: Cristinziano, Leonardo, et al.
Publicado: (2022)

Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization
por: Mallardo, Domenico, et al.
Publicado: (2022)

Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients
por: Galati, Domenico, et al.
Publicado: (2023)

Epigenetic Regulation in Melanoma: Facts and Hopes
por: Giunta, Emilio Francesco, et al.
Publicado: (2021)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

How we treat locoregional melanoma
por: Troiani, T., et al.
Publicado: (2021)

Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy
por: Ascierto, Maria Libera, et al.
Publicado: (2015)

The role of spectrophotometry in the diagnosis of melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2010)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Immunotherapy in non-melanoma skin cancer: updates and new perspectives
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab
por: Simeone, Ester, et al.
Publicado: (2014)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
por: Ralli, Massimo, et al.
Publicado: (2020)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19
por: Trojaniello, C., et al.
Publicado: (2021)

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
por: Caracò, Corrado, et al.
Publicado: (2013)

Do BRAF inhibitors select for populations with different disease progression kinetics?
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?
por: Scarpa, Raffaele, et al.
Publicado: (2020)

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2019)

Nevoid melanoma of the vagina: report of one case diagnosed on thin layer cytological preparations
por: Fulciniti, Franco, et al.
Publicado: (2007)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
por: Guida, Michele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ou7ouhqn59c3jhekvgq4orrpdi